CN101076540B - 产生肿瘤坏死因子相关的凋亡诱导配体的工程化肿瘤归巢细胞 - Google Patents

产生肿瘤坏死因子相关的凋亡诱导配体的工程化肿瘤归巢细胞 Download PDF

Info

Publication number
CN101076540B
CN101076540B CN2005800324298A CN200580032429A CN101076540B CN 101076540 B CN101076540 B CN 101076540B CN 2005800324298 A CN2005800324298 A CN 2005800324298A CN 200580032429 A CN200580032429 A CN 200580032429A CN 101076540 B CN101076540 B CN 101076540B
Authority
CN
China
Prior art keywords
cells
trail
tumor
apoptosis
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800324298A
Other languages
English (en)
Chinese (zh)
Other versions
CN101076540A (zh
Inventor
A·M·詹尼
C·卡洛-斯特拉
F·科洛塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Dompe PhaRMa SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe SpA, Dompe PhaRMa SpA filed Critical Dompe SpA
Publication of CN101076540A publication Critical patent/CN101076540A/zh
Application granted granted Critical
Publication of CN101076540B publication Critical patent/CN101076540B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2005800324298A 2004-07-29 2005-07-21 产生肿瘤坏死因子相关的凋亡诱导配体的工程化肿瘤归巢细胞 Expired - Fee Related CN101076540B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04017907.9 2004-07-29
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (2)

Publication Number Publication Date
CN101076540A CN101076540A (zh) 2007-11-21
CN101076540B true CN101076540B (zh) 2012-10-24

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800324298A Expired - Fee Related CN101076540B (zh) 2004-07-29 2005-07-21 产生肿瘤坏死因子相关的凋亡诱导配体的工程化肿瘤归巢细胞

Country Status (24)

Country Link
US (1) US20070264231A1 (enExample)
EP (2) EP1621550A1 (enExample)
JP (1) JP5042826B2 (enExample)
KR (1) KR20070047757A (enExample)
CN (1) CN101076540B (enExample)
AT (1) ATE455847T1 (enExample)
AU (1) AU2005266543B2 (enExample)
BR (1) BRPI0513855A (enExample)
CA (1) CA2571426A1 (enExample)
DE (1) DE602005019050D1 (enExample)
DK (1) DK1771468T3 (enExample)
ES (1) ES2340400T3 (enExample)
HR (1) HRP20100227T1 (enExample)
IL (1) IL180233A (enExample)
MX (1) MX2007001152A (enExample)
NO (1) NO20070956L (enExample)
NZ (1) NZ552223A (enExample)
PL (1) PL1771468T3 (enExample)
PT (1) PT1771468E (enExample)
RS (1) RS51381B (enExample)
RU (1) RU2390558C2 (enExample)
SI (1) SI1771468T1 (enExample)
WO (1) WO2006010558A1 (enExample)
ZA (1) ZA200701231B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510886A (pt) * 2004-06-18 2007-12-26 Genentech Inc método para aumentar a apoptose ou a citotoxicidade em células de mamìferos
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
US20140369979A1 (en) * 2012-02-01 2014-12-18 Postech Academy-Industry Foundation Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
RU2716821C2 (ru) 2014-10-24 2020-03-17 Калиди Биотерапьютикс, Инк. Комбинированный иммунотерапевтический подход к лечению рака
EP3971284B1 (en) * 2015-07-29 2023-11-08 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
WO2020188105A1 (en) 2019-03-21 2020-09-24 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU747602B2 (en) * 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
JP2004526666A (ja) * 2000-09-11 2004-09-02 マスク ファウンデーション フォー リサーチ デヴェロップメント アポトーシスの選択的誘導によって腫瘍を治療するための組成物及び方法
AU2001297677B2 (en) * 2000-10-24 2007-07-05 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
E Ucur et al.Induction of apoptosis in experimental human B celllymphomas by conditional TRAIL-expressing T cells.British Journal of Cancer89 11.2003,89(11),2155 -2162.
E Ucur et al.Induction of apoptosis in experimental human B celllymphomas by conditional TRAIL-expressing T cells.British Journal of Cancer89 11.2003,89(11),2155-2162. *
Javier García-Castro et al.Antitumoral cell-based therapies.Cancer Therapy1.2003,1163-171. *
Jeongwu Lee,et al.Cellular and Genetic Characterization of Human Adult BoneMarrow-Derived Neural Stem-Like Cells: A PotentialAntiglioma Cellular Vector.CANCER RESEARCH63 24.2003,63(24),8877-8889.
Jeongwu Lee,et al.Cellular and Genetic Characterization of Human Adult BoneMarrow-Derived Neural Stem-Like Cells: A PotentialAntiglioma Cellular Vector.CANCER RESEARCH63 24.2003,63(24),8877-8889. *
Mark J. Smyth,et al.Tumor Necrosis Factor–related Apoptosis-inducing Ligand(TRAIL) Contributes to Interferon -dependent Natural KillerCell Protection from Tumor Metastasis.JOURNAL OF EXPERIMENTAL MEDICINE193 6.2001,193(6),661-670.
Mark J. Smyth,et al.Tumor Necrosis Factor–related Apoptosis-inducing Ligand(TRAIL) Contributes to Interferon -dependent Natural KillerCell Protection from Tumor Metastasis.JOURNAL OF EXPERIMENTAL MEDICINE193 6.2001,193(6),661-670. *

Also Published As

Publication number Publication date
EP1771468A1 (en) 2007-04-11
BRPI0513855A (pt) 2008-05-20
ZA200701231B (en) 2008-08-27
RS51381B (sr) 2011-02-28
AU2005266543B2 (en) 2012-02-02
MX2007001152A (es) 2007-04-18
DE602005019050D1 (de) 2010-03-11
ES2340400T3 (es) 2010-06-02
IL180233A0 (en) 2007-07-04
JP5042826B2 (ja) 2012-10-03
RU2390558C2 (ru) 2010-05-27
US20070264231A1 (en) 2007-11-15
KR20070047757A (ko) 2007-05-07
DK1771468T3 (da) 2010-05-25
EP1771468B1 (en) 2010-01-20
SI1771468T1 (sl) 2010-07-30
WO2006010558A1 (en) 2006-02-02
IL180233A (en) 2010-12-30
WO2006010558A8 (en) 2006-08-24
AU2005266543A1 (en) 2006-02-02
RU2007107369A (ru) 2008-09-10
JP2008507961A (ja) 2008-03-21
NO20070956L (no) 2007-02-20
NZ552223A (en) 2009-01-31
CA2571426A1 (en) 2006-02-02
PL1771468T3 (pl) 2010-07-30
HRP20100227T1 (hr) 2010-07-31
CN101076540A (zh) 2007-11-21
ATE455847T1 (de) 2010-02-15
PT1771468E (pt) 2010-04-20
EP1621550A1 (en) 2006-02-01
HK1110874A1 (en) 2008-07-25

Similar Documents

Publication Publication Date Title
CN101076540B (zh) 产生肿瘤坏死因子相关的凋亡诱导配体的工程化肿瘤归巢细胞
JP2022113883A (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞組成物
Redeker et al. Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination
JP2023107931A (ja) 免疫療法のための組成物および方法
CN106659742A (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
US20240180983A1 (en) Adenovirus encoding il-15
JP2017093426A (ja) １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN111849916A (zh) 一种免疫细胞及其制剂与应用
CN105384820A (zh) 嵌合抗原受体及其基因和重组表达载体、工程化cd19靶向性的nkt细胞及其应用
Meazza et al. Interleukin (IL)‐15 induces survival and proliferation of the growth factor‐dependent acute myeloid leukemia M‐07e through the IL‐2 receptor β/γ
CN117304342A (zh) 嵌合抗原受体及其应用
CN113416260B (zh) 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
Grisendi et al. Tumor stroma manipulation by MSC
US20240408202A1 (en) FOLATE RECEPTOR ALPHA -TARGETING BI-SPECIFIC T CELL ENGAGERS (BiTEs) AND USES THEREOF
HK1110874B (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
CN114350616A (zh) 一种免疫细胞及其制备方法和应用
CN116059329A (zh) 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法
Qian et al. Gene therapy of cancer: induction of anti-tumor immunity
CN115605586B (zh) 工程化溶瘤腺病毒
We Kim et al. Murine bone marrow stromal cells: implications for their use in gene modified cell therapy
WO2025103498A1 (zh) 一种靶向cd38和cll1的双特异性嵌合抗原受体及其应用
KR20250174161A (ko) 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
Goding Induction of anti-tumor responses via adoptively transferred, cytokine-gene transduced A-NK cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1110874

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: DOMPE S.P.A.

Free format text: FORMER OWNER: DOMPE PHA R. MA S. P. A.

Effective date: 20111031

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20111031

Address after: Italy Aquila

Applicant after: Dompe S. P. A.

Address before: Italy Aquila

Applicant before: Dompe Pha R. Ma S. P. A.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1110874

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121024

Termination date: 20130721